HRP20130115T4 - Postupci liječenja poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata - Google Patents
Postupci liječenja poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata Download PDFInfo
- Publication number
- HRP20130115T4 HRP20130115T4 HRP20130115TT HRP20130115T HRP20130115T4 HR P20130115 T4 HRP20130115 T4 HR P20130115T4 HR P20130115T T HRP20130115T T HR P20130115TT HR P20130115 T HRP20130115 T HR P20130115T HR P20130115 T4 HRP20130115 T4 HR P20130115T4
- Authority
- HR
- Croatia
- Prior art keywords
- mtp inhibitor
- use according
- day
- dose level
- dosage units
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 9
- 208000035475 disorder Diseases 0.000 title claims 8
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims 6
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims 5
- 201000010099 disease Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims 40
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 36
- CUCJJMLDIUSNPU-UHFFFAOYSA-N 1-oxidopiperidin-1-ium Chemical compound [O-][NH+]1CCCCC1 CUCJJMLDIUSNPU-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 5
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 4
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 229940125753 fibrate Drugs 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 102000023984 PPAR alpha Human genes 0.000 claims 2
- 108010028924 PPAR alpha Proteins 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 229920000080 bile acid sequestrant Polymers 0.000 claims 2
- 229940096699 bile acid sequestrants Drugs 0.000 claims 2
- 230000001906 cholesterol absorption Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960000815 ezetimibe Drugs 0.000 claims 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000002814 niacins Chemical class 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 2
- 229960003912 probucol Drugs 0.000 claims 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 2
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 2
- 150000001467 thiazolidinediones Chemical class 0.000 claims 2
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 1
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (24)
1. Uporaba inhibitora MTP u proizvodnji lijeka za liječenja subjekta koji pati od poremećaja povezanog s hiperlipidemijom i/ili hiperkolesterolemijom, naznačen time što navedeno liječenje sadrži primjenu najmanje tri postupno rastuće doze navedenog inhibitora MTP na navedenog subjekta, i gdje navedeni inhibitor MTP ima strukturu:
[image]
ili njegove farmaceutski prihvatljive soli ili njegovog piperidin N-oksida.
2. Inhibitor MTP za uporabu u liječenju subjekta koji pati od poremećaja povezanog sa hiperlipidemijom i/ili hiperkolesterolemijom, naznačen time što navedeno liječenje sadrži primjenu najmanje tri postupno rastuće doze navedenog inhibitora MTP na navedenog subjekta, i gdje navedeni inhibitor MTP ima strukturu:
[image]
ili njegove farmaceutski prihvatljive soli ili njegovog piperidin N-oksida.
3. Uporaba sukladno patentnom zahtjevu 1 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 2, naznačeni time što je poremećaj teška hiperkolesterolemija.
4. Uporaba sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 3 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 2 ili patentnom zahtjevu 3, naznačeni time što se inhibitor MTP primjenjuje oralno.
5. Uporaba sukladno bilo kojem od patentnih zahtjeva 1, 3 i 4 ili inhibitor MTP za uporabu sukladno bilo kojem od patentnih zahtjeva 2 do 4, naznačena time što navedene rastuće doze sadrže najmanje prvu razinu doze, drugu razinu doze i treću razinu doze.
6. Uporaba sukladno patentnom zahtjevu 5 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 5, naznačeni time što navedene rastuće doze nadalje sadrže četvrtu razinu doze.
7. Uporaba sukladno patentnom zahtjevu 5 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 5, naznačeni time što navedene rastuće doze nadalje sadrže četvrtu i petu razinu doze.
8. Uporaba sukladno patentnom zahtjevu 7 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 7, naznačeni time što je prva razina doze 6.25 mg/dan, druga razina doze je 12.5 mg/dan, treća razina doze je 25 mg/dan, ćetvrta razina doze je 37.5 mg/dan i peta razina doze je 50 mg/dan.
9. Uporaba sukladno bilo kojem od patentnih zahtjeva 1 i 3 do 7 ili inhibitor MTP za uporabu sukladno bilo kojem od patentnih zahtjeva 2 do 7, naznačeni time što svaka od navedenih rastućih doza nije viša od 50% od neposredno slijedeće razine doze.
10. Uporaba sukladno bilo kojem od patentnih zahtjeva 1 i 3 do 7 ili inhibitor MTP za uporabu sukladno bilo kojem od patentnih zahtjeva 2 do 7, naznačeni time što svaka od navedenih rastućih razina doze nije viša od 20% od neposredno slijedeće razine doze.
11. Uporaba sukladno patentnom zahtjevu 7 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 7, naznačeni time što je navedena prva razina doze od oko 2 do oko 13 mg/dan, navedena druga razina doze je od oko 5 do oko 30 mg/dan, navedena treća razina doze je od oko 10 do oko 50 mg/dan, navedena četvrta razina doze je od oko 20 do oko 60 mg/dan, i navedena peta razina doze je od oko 30 do oko 75 mg/dan.
12. Uporaba sukladno patentnom zahtjevu 6 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 6, naznačeni time što je prva razina doze 12.5 mg/dan, druga razina doze je 25 mg/dan, treća razina doze je 37.5 mg/dan i četvrta razina dozeje 50 mg/dan.
13. Uporaba sukladno patentnom zahtjevu 5 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 5, naznačeni time što je, prva razina doze 6.25 mg/dan, druga razina doze 12.5 mg/dan i treća razina doze 50 mg/dan.
14. Uporaba sukladno bilo kojem od patentnih zahtjeva 1 i 3 do 13 ili inhibitor MTP za uporabu sukladno bilo kojem od patentnih zahtjeva 2 do 13, naznačeni time što se navedeni inhibitor MTP primjenuje na navedenog subjekta u kombinaciji s dodatnim spojem za modifikaciju lipida.
15. Uporaba sukladno patentnom zahtjevu 14 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 14, naznačeni time što su spojevi za modifikaciju lipida izabrani iz grupe koju čine inhibitori HMG CoA reduktaze, inhibitori apsorpcije kolesterola, ezetimib, inhibitori skvalen sintetaze, fibrati, sekvestranti žučne kiseline, statini, probukol i derivati, niacin, derivati niacina, agonisti PPAR alfa, fibrati, agonisti PPAR gama, tiazolidindioni i inhibitori proteina za transfer kolesterol estera (CETP).
16. Uporaba sukladno bilo kojem od patentnih zahtjeva 1 i 3 do 13 ili inhibitor MTP za uporabu sukladno bilo kojem od patentnih zahtjeva 2 do 13, naznačeni time što se svaka razina doze primjenjuje na subjekta od oko 1 do 4 tjedna.
17. Uporaba sukladno patentnom zahtjevu 14 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 14, naznačeni time što su inhibitor MTP i spojevi za modifikaciju lipida prisutni u istoj jedinici doze.
18. Uporaba inhibitora MTP u proizvodnji lijeka za liječenje subjekta koji pati od poremećaja koji je izabran iz grupe koju čine ili homozigotna/heterozigotna porodična hiperkolesterolemija ili hipertrigliceridemija, gdje navedeni inhibitor MTP ima strukturu:
[image]
ili njegove farmaceutski prihvatljive soli ili njegovog piperidin N-oksida.
19. Inhibitor MTP za uporabu u liječenju subjekta koji pati od poremećaja izabranog iz grupe koja se sastoji od homozigotne/heterozigotne porodične hiperkolesterolemije ili hipertrigliceridemije, gdje navedeni inhibitor MTP ima strukturu:
[image]
ili njegove farmaceutski prihvatljive soli ili njegovog piperidin N-oksida.
20. Uporaba sukladno patentnom zahtjevu 18 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 19 , naznačeni time što se navedeni inhibitor MTP primjenjuje na navedenog subjekta u kombinaciji sa dodatnim spojem za modifikaciju lipida.
21. Uporaba sukladno patentnom zahtjevu 18 ili patentnom zahtjevu 20 ili inhibitor MTP za uporabu sukladno patentnom zahtjevu 19 ili patentnom zahtjevu 20, naznačeni time što su jedan ili više od ukupnog kolesterola, LDL, triglicerida u stanju gladovanja (TG), VLDL, lipoproteina (a) (Lp(a)), i apolipoproteina A-I, A-II, B i E sniženi za najmanje 15%, u usporedbi s kontrolnim razinama.
22. Uporaba sukladno bilo kojem od patentnih zahtjeva 18, 20 i 21 ili inhibitor MTP prema bilo kojem od patentnih zahtjeva 19 do 21, naznačeni time što su spojevi za modifikaciju lipida izabrani iz grupe koja se sastoji od inhibitora HMG CoA reduktaze, inhibitora apsorpcije kolesterola, ezetimiba, inhibitora skvalen sintetaze, fibrata, sekvestranata žučne kiseline, statina, probukola i derivata, niacina, derivata niacina, agonista PPAR alfa, fibrata, agonista PPAR gama, tiazolidindiona i inhibitora proteina za transfer kolesterol estera (CETP).
23. Komplet za liječenje poremećaja povezanog s hiperlipidemijom i/ili hiperkolesterolemijom kod subjekta, naznačen time što sadrži:
a) najmanje četiri seta farmaceutskih jedinica doze inhibitora MTP, pri čemu prvi set jedinica doze osigurava 6-25 mg/dan za prvi interval, drugi set jedinica doze osigurava 12.5 mg/dan za drugi interval, treći set jedinica doze osigurava 37.5 mg/dan za treći interval, četvrti set jedinica doze osigurava 50 mg/dan za četvrti interval; i
b) upute za uporabu, gdje navedeni inhibitor MTP ima strukturu:
[image]
ili njegove farmaceutski prihvatljive soli ili njegovog piperidin N-oksida.
24. Komplet za liječenje poremećaja koji je povezan sa hiperlipidemijom i/ili hiperkolesterolemijom kod subjekta, naznačen time što sadrži:
a) najmanje pet setova farmaceutskih jedinica doze inhibitora MTP, pri čemu prvi set jedinica doze osigurava od oko 2 do oko 13 mg/dan za prvi interval, drugi set jedinica doze osigurava od oko 5 do oko 30 mg/dan za drugi interval, treći set jedinica doze osigurava od oko 10 do oko 50 mg/dan za treći interval, četvrti set jedinica doze osigurava od oko 20 do oko 60 mg/dan za četvrti interval i peti set jedinica doze osigurava od oko 30 do oko 75 mg/dan za peti interval; i
b) upute za uporabu,
gdje navedeni inhibitor MTP ima strukturu:
[image]
ili njegove farmaceutski prihvatljive soli ili njegovog piperidin N-oksida.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55091504P | 2004-03-05 | 2004-03-05 | |
| PCT/US2005/007435 WO2005087234A1 (en) | 2004-03-05 | 2005-03-07 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
| EP05724887.4A EP1725234B2 (en) | 2004-03-05 | 2005-03-07 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20130115T1 HRP20130115T1 (hr) | 2013-03-31 |
| HRP20130115T4 true HRP20130115T4 (hr) | 2016-04-22 |
Family
ID=34975320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130115TT HRP20130115T4 (hr) | 2004-03-05 | 2013-02-08 | Postupci liječenja poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata |
Country Status (19)
| Country | Link |
|---|---|
| US (11) | US7932268B2 (hr) |
| EP (1) | EP1725234B2 (hr) |
| JP (4) | JP5697296B2 (hr) |
| KR (2) | KR101494067B1 (hr) |
| AU (1) | AU2005221656B2 (hr) |
| CA (2) | CA2558766A1 (hr) |
| CY (2) | CY1114218T1 (hr) |
| DK (1) | DK1725234T4 (hr) |
| ES (1) | ES2399721T5 (hr) |
| HR (1) | HRP20130115T4 (hr) |
| LT (1) | LTC1725234I2 (hr) |
| ME (1) | ME02070B (hr) |
| NL (1) | NL300634I2 (hr) |
| NZ (1) | NZ549721A (hr) |
| PL (1) | PL1725234T5 (hr) |
| PT (1) | PT1725234E (hr) |
| RS (1) | RS52825B2 (hr) |
| SI (2) | SI1725234T1 (hr) |
| WO (1) | WO2005087234A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52825B2 (sr) | 2004-03-05 | 2018-03-30 | Univ Pennsylvania | Postupci za lečenje poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperholesterolemijom uz minimizaciju sporednih efekata |
| US20070088089A1 (en) * | 2005-10-18 | 2007-04-19 | Wisler Gerald L | Methods for treating disorders associated with hyperlipidemia in a mammal |
| CA2661404A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| WO2008072056A1 (en) * | 2006-12-14 | 2008-06-19 | Pfizer Limited | Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation |
| US20080161279A1 (en) * | 2006-12-21 | 2008-07-03 | Wisler Gerald L | Methods of Treating Obesity |
| JP5875097B2 (ja) * | 2009-12-11 | 2016-03-02 | 学校法人東邦大学 | 脂質取り込み抑制剤 |
| KR20160079124A (ko) | 2013-11-20 | 2016-07-05 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | 동질접합성 가족성 과콜레스테롤증의 치료 |
| CN103690960A (zh) * | 2013-12-18 | 2014-04-02 | 北京科源创欣科技有限公司 | 甲磺酸洛美他派药物组合物及制备方法 |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| WO2015143178A1 (en) | 2014-03-20 | 2015-09-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| SI3129018T1 (sl) | 2014-04-11 | 2020-02-28 | Cymabay Therapeutics, Inc. | Zdravljenje nafld in nash |
| BR102015025502B1 (pt) * | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| WO2016181409A1 (en) | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | Saroglitazar magnesium for the treatment of chylomicronemia syndrome - |
| US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| JP2023536855A (ja) * | 2020-07-29 | 2023-08-30 | アムリット・ファーマシューティカルズ・インコーポレイテッド | 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド |
| US20240165093A1 (en) | 2021-03-03 | 2024-05-23 | Amryt Pharmaceuticals Inc. | Methods for treating familial chylomicronemia syndrome |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1722496A (en) | 1926-07-29 | 1929-07-30 | William B Chapman | Boiler and method of operating the same |
| US1725396A (en) | 1927-05-16 | 1929-08-20 | Int Harvester Co | Plow |
| US1725496A (en) | 1927-12-27 | 1929-08-20 | John R Ketchum | Oil-well pump |
| US2821696A (en) | 1953-11-25 | 1958-01-28 | Hughes Aircraft Co | Electronic multiple comparator |
| JPS5612114B2 (hr) | 1974-06-07 | 1981-03-18 | ||
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
| US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
| CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
| US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
| US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
| US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
| DE3581638D1 (de) | 1984-12-04 | 1991-03-07 | Sandoz Ag | Inden-analoga von mevalonolakton und ihre derivate. |
| US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
| KR900001212B1 (ko) | 1985-10-25 | 1990-02-28 | 산도즈 파마슈티칼스 코오포레이숀 | 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도 |
| FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
| US4716175A (en) | 1987-02-24 | 1987-12-29 | Warner-Lambert Company | Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase |
| ES2009918A6 (es) | 1987-05-22 | 1989-10-16 | Squibb & Sons Inc | Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo. |
| US5015644A (en) | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
| US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
| NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
| KR930005040B1 (ko) | 1989-08-31 | 1993-06-12 | 주식회사 금성사 | 식기 건조기 겸용 전자레인지 및 그 구동제어방법 |
| US5026554A (en) | 1990-09-13 | 1991-06-25 | Merck & Co., Inc. | Method of inhibiting fungal growth using squalene synthetase inhibitors |
| HU218419B (hu) | 1992-03-06 | 2000-08-28 | E.R. Squibb And Sons, Inc. | Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5712396A (en) | 1992-10-28 | 1998-01-27 | Magnin; David R. | α-phosphonosulfonate squalene synthetase inhibitors |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| DE4435477A1 (de) | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
| US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
| US5536859A (en) | 1995-02-27 | 1996-07-16 | Amoco Corporation | Alpha-olefin catalyst and process |
| GB9504066D0 (en) | 1995-03-01 | 1995-04-19 | Pharmacia Spa | Phosphate derivatives of ureas and thioureas |
| PT832069E (pt) | 1995-06-07 | 2003-06-30 | Pfizer | Derivados de tetrahidro-isoquinolin-6-il amida do acido bifenilo-2-carboxilico sua preparacao e sua utilizacao como inibidores de proteina de transferencia de triglicerido microsomal e/ou da secrecao de apolipoproteina b (apo b) |
| EP0832069B1 (en) | 1995-06-07 | 2003-03-05 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| DE19546919A1 (de) | 1995-12-15 | 1997-06-19 | Bayer Ag | N-Heterocyclisch substituierte Phenylessigsäure-Derivate |
| DE19546918A1 (de) | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclische Heterocyclen |
| DE19613550A1 (de) | 1996-04-04 | 1997-10-09 | Bayer Ag | Neue Pyrimido[1,2-a]indole |
| US6774236B1 (en) | 1996-04-04 | 2004-08-10 | Bayer Aktiengesellschaft | Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives |
| DE19613549A1 (de) | 1996-04-04 | 1997-10-09 | Bayer Ag | Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate |
| DE19615265A1 (de) | 1996-04-18 | 1997-12-04 | Bayer Ag | Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole |
| ATE223400T1 (de) | 1996-04-30 | 2002-09-15 | Pfizer | Verfahren und zwischenprodukte zur herstellung von 4-trifluoromethylbiphenyl-2-carbonsaüre,(2- (2h-(1,2,4) triazol-3-ylmethyl)-1,2,3,4- tetrahydro-isoquinolin-6-yl)-amide |
| US6057339A (en) | 1996-05-09 | 2000-05-02 | Bristol-Myers Squibb Company | Method of inhibiting or treating phytosterolemia with an MTP inhibitor |
| US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| JP2002513379A (ja) | 1996-07-24 | 2002-05-08 | ブリストル―マイヤーズ・スクイブ・カンパニー | Ｍｔｐ抑制因子を用いる、高ｌｄｌの必要を持つ腫瘍の治療法 |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| KR100334567B1 (ko) | 1996-11-27 | 2002-05-03 | 디. 제이. 우드, 스피겔 알렌 제이 | 아포 비-분비/엠티피 억제성 아미드 |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| AU5513298A (en) | 1996-12-20 | 1998-07-17 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of microsomal triglyceride transfer protein and method |
| WO1998031366A1 (en) | 1997-01-17 | 1998-07-23 | Bristol-Myers Squibb Company | Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs |
| AU6023298A (en) | 1997-01-17 | 1998-08-07 | Bristol-Myers Squibb Company | A method of inhibiting or treating phytosterolemia with an mtp inhibitor |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| AU748608B2 (en) | 1997-05-01 | 2002-06-06 | Bristol-Myers Squibb Company | MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels |
| US5990110A (en) | 1997-07-15 | 1999-11-23 | Bristol-Meyers Squibb Company | Method for treating tumors having high LDL requirements employing MTP inhibitors |
| US20030153541A1 (en) | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| US20020045271A1 (en) | 1998-06-10 | 2002-04-18 | Licata And Tyrrell P.C. | Compounds and methods for identifying compounds that interact with microsomal triglyceride transfer protein binding sites on apolipoprotein b and modulate lipid biosynthesis |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| EP1113801A4 (en) | 1998-09-17 | 2002-10-02 | Bristol Myers Squibb Co | METHOD FOR TREATING ATHEROSCLEROSIS WITH AN AP2 INHIBITOR OR COMBINATION |
| US7358254B2 (en) | 2001-07-13 | 2008-04-15 | Bristol-Myers Squibb Company | Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| US6509348B1 (en) | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| IL133201A0 (en) | 1998-12-04 | 2001-03-19 | Pfizer Prod Inc | Lowering blood levels of lipoproten (a) |
| EA200100704A1 (ru) | 1998-12-23 | 2002-02-28 | Джи.Ди.Сирл Ллс | Комбинация для применения по сердечно-сосудистым показаниям |
| US6344450B1 (en) | 1999-02-09 | 2002-02-05 | Bristol-Myers Squibb Company | Lactam compounds and their use as inhibitors of serine proteases and method |
| US6297233B1 (en) | 1999-02-09 | 2001-10-02 | Bristol-Myers Squibb Company | Lactam inhibitors of FXa and method |
| DE60018225T2 (de) * | 1999-03-01 | 2005-12-29 | Pfizer Products Inc., Groton | Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor |
| US6582698B1 (en) | 1999-03-19 | 2003-06-24 | Genentech, Inc. | Treatment method |
| CA2345753A1 (en) | 1999-07-30 | 2001-02-08 | Hendrik Jan Verkade | A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces |
| DE19951022A1 (de) | 1999-10-22 | 2001-04-26 | Bayer Ag | Carbolinderivate |
| IL139450A0 (en) | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
| US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US6620821B2 (en) | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US6812345B2 (en) | 2000-06-15 | 2004-11-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| DE10030375A1 (de) | 2000-06-21 | 2002-01-03 | Bayer Ag | Verwendung von MTP-Inhibitoren zur Senkung von ppTRL |
| US6649770B1 (en) | 2000-11-27 | 2003-11-18 | Ciba Specialty Chemicals Corporation | Substituted 5-aryl-2-(2-hydroxyphenyl)-2H-benzotriazole UV absorbers, compositions stabilized therewith and process for preparation thereof |
| IL156552A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| JP2002220345A (ja) | 2001-01-24 | 2002-08-09 | Sumitomo Pharmaceut Co Ltd | 脂肪肝改善剤 |
| ES2286233T3 (es) | 2001-01-26 | 2007-12-01 | Schering Corporation | Combinaciones de inhibidor(es) de la absorcion de esteroles con agente(s) cardiovascular(es) para el tratamiento de afecciones vasculares. |
| EE05452B1 (et) | 2001-06-28 | 2011-08-15 | Pfizer Products Inc. | Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid |
| US6884812B2 (en) | 2001-08-31 | 2005-04-26 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US6916813B2 (en) | 2001-12-10 | 2005-07-12 | Bristol-Myers Squibb Co. | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
| TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| US20030162788A1 (en) | 2002-01-10 | 2003-08-28 | Boehringer Ingelheim Pharma Kg | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals |
| CN101838218A (zh) | 2002-02-28 | 2010-09-22 | 日本烟草产业株式会社 | 酯化合物及其医药用途 |
| JP3662566B2 (ja) * | 2002-02-28 | 2005-06-22 | 日本たばこ産業株式会社 | エステル化合物及びその医薬用途 |
| KR101120337B1 (ko) | 2002-07-09 | 2012-02-29 | 브리스톨-마이어스 스큅 컴퍼니 | 항당뇨제 및 항비만제로서 유용한 치환된 헤테로시클릭유도체 및 방법 |
| UA83003C2 (ru) | 2002-07-23 | 2008-06-10 | Басф Акциенгезелльшафт | Гербицидная смесь с синергическим действием, гербицидная композиция на ее основе, метод получения и метод борьбы с нежелательной растительностью |
| WO2004028544A1 (en) | 2002-09-25 | 2004-04-08 | Novo Nordisk A/S | Use of mas-compounds for treating diseases associated with lipid metabolism |
| US20050090426A1 (en) | 2003-03-24 | 2005-04-28 | Blumberg Richard S. | Methods of inhibiting inflammation |
| US6846836B2 (en) | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
| US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
| WO2005000217A2 (en) | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
| WO2004110368A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of hypertension |
| US20040253923A1 (en) * | 2003-06-12 | 2004-12-16 | Braley Richard C. | System and method for electronically pairing devices |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| WO2005018436A2 (en) | 2003-08-26 | 2005-03-03 | The Trustees Of Boston University | Methods for the diagnosis, prognosis and treatment of metabolic syndrome |
| JP4832897B2 (ja) | 2003-08-29 | 2011-12-07 | 日本たばこ産業株式会社 | エステル誘導体及びその医薬用途 |
| US7153976B2 (en) | 2003-10-06 | 2006-12-26 | Pfizer Inc. | Purification process for an azabicyclo[3.1.0]hexane compound |
| EP1522541A1 (en) | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
| CN1886393A (zh) * | 2003-10-08 | 2006-12-27 | 沃泰克斯药物股份有限公司 | 含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂 |
| EP1680099B1 (en) | 2003-11-07 | 2009-04-15 | JJ Pharma, Inc. | Hdl-boosting combination therapy complexes |
| WO2005051382A1 (ja) | 2003-11-28 | 2005-06-09 | Astellas Pharma Inc. | 脂質低下作用増強剤 |
| AU2005209115A1 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
| JP2007526309A (ja) | 2004-03-02 | 2007-09-13 | アベール ファーマシューティカルズ インコーポレイテッド | 生物活性剤の混合製剤またはキット |
| RS52825B2 (sr) | 2004-03-05 | 2018-03-30 | Univ Pennsylvania | Postupci za lečenje poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperholesterolemijom uz minimizaciju sporednih efekata |
| WO2005085466A2 (en) | 2004-03-09 | 2005-09-15 | Bayer Healtcare Ag | Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2) |
| GB0405459D0 (en) | 2004-03-11 | 2004-04-21 | Shea Clayton O | Skipping ropes |
| WO2005094864A2 (en) | 2004-03-30 | 2005-10-13 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis |
| EP1737460A2 (en) | 2004-04-09 | 2007-01-03 | Janssen Pharmaceutica N.V. | Intermittent dosing regimen for the treatment of overweight with mtp-inhibitors |
| BRPI0512856A (pt) | 2004-06-30 | 2008-04-08 | Combinatorx Inc | métodos e reagentes para o tratamento de distúrbios metabólicos |
| JP4782991B2 (ja) | 2004-06-30 | 2011-09-28 | 株式会社東芝 | 情報処理機器および情報処理機器の表示制御方法 |
| KR20070072888A (ko) | 2004-10-25 | 2007-07-06 | 니뽄 다바코 산교 가부시키가이샤 | 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법 |
| EA014420B1 (ru) | 2004-12-06 | 2010-12-30 | Релайэнт Фармасьютикалз, Инк. | Омега-3 жирные кислоты и дислипидемический агент для липидной терапии |
| NZ554734A (en) | 2004-12-08 | 2009-03-31 | Sirion Therapeutics Inc | Methods, Assays And Compositions For Treating Retinol-Related Diseases |
| US20060252733A1 (en) | 2005-04-07 | 2006-11-09 | Novelix Pharmaceuticals, Inc. | Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism |
| WO2006108666A1 (en) | 2005-04-13 | 2006-10-19 | Proteosys Ag | Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases |
| FR2884831B1 (fr) | 2005-04-22 | 2007-08-10 | Merck Sante Soc Par Actions Si | Methode de criblage de composes inhibiteurs de la mtp |
| EP1890767A2 (en) | 2005-05-27 | 2008-02-27 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| BRPI0616002B1 (pt) | 2005-09-13 | 2016-04-19 | Bayer Cropscience Ag | composto derivado de fenil-amidina, processo de preparação de composto, método de controle de fungos fitopatogênicos de safras e método de controle de insetos daninhos |
| US20070088089A1 (en) | 2005-10-18 | 2007-04-19 | Wisler Gerald L | Methods for treating disorders associated with hyperlipidemia in a mammal |
| CN101291662A (zh) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
| US20080051427A1 (en) | 2006-05-18 | 2008-02-28 | Fritz Schuckler | Pharmaceutical Compositions and Methods of Using Same |
| AU2007254827A1 (en) | 2006-06-02 | 2007-12-13 | San Diego State University Research Foundation | Compositions and methods for ameliorating hyperlipidemia |
| US20090042835A1 (en) | 2006-06-02 | 2009-02-12 | Davis Roger A | Compositions and methods for ameliorating hyperlipidemia |
| CA2654098A1 (en) | 2006-06-13 | 2007-12-21 | Merck Frosst Canada Ltd. | Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US20080016127A1 (en) | 2006-06-30 | 2008-01-17 | Microsoft Corporation | Utilizing software for backing up and recovering data |
| DE102006034907A1 (de) | 2006-07-28 | 2008-01-31 | Carl Zeiss Microimaging Gmbh | Laser-Scanning-Mikroskop |
| US20080033019A1 (en) | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
| US20100310553A1 (en) | 2006-08-14 | 2010-12-09 | Guangxiang Luo | Compositions and Methods for Controlling Hepatitis C Virus Infection |
| CA2661404A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| WO2008072061A1 (en) | 2006-12-14 | 2008-06-19 | Pfizer Products Inc. | Method of treatment of obesity with an mtp inhibitor in conjunction with an increased-fat diet |
| WO2008075949A1 (en) | 2006-12-20 | 2008-06-26 | Friesland Brands B.V. | Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms |
| US20080161279A1 (en) | 2006-12-21 | 2008-07-03 | Wisler Gerald L | Methods of Treating Obesity |
| US7645732B2 (en) | 2007-01-24 | 2010-01-12 | Board Of Regents, The University Of Texas System | Treating hepatitis C virus infection |
| WO2008090198A1 (en) | 2007-01-25 | 2008-07-31 | Janssen Pharmaceutica Nv | Use of mtp inhibitors for increasing levels of satiety hormones |
| WO2008115574A1 (en) | 2007-03-21 | 2008-09-25 | Reliant Pharmaceuticals, Inc. | Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same |
| FR2922945B1 (fr) | 2007-10-31 | 2009-11-27 | Peugeot Citroen Automobiles Sa | Procede de determination d'intervalle de maintenance pour vehicule automobile. |
| WO2010083280A2 (en) | 2009-01-14 | 2010-07-22 | Aegerion Pharmaceuticals, Inc. | Methods for treating obesity and disorders associated with hyperlipidemia in a mammal |
| US9069114B2 (en) | 2010-07-23 | 2015-06-30 | Prysmian S.P.A. | Bend-resistant single-mode optical fibre |
-
2005
- 2005-03-07 RS RS20130054A patent/RS52825B2/sr unknown
- 2005-03-07 KR KR1020127034021A patent/KR101494067B1/ko active IP Right Grant
- 2005-03-07 ES ES05724887T patent/ES2399721T5/es active Active
- 2005-03-07 DK DK05724887.4T patent/DK1725234T4/en active
- 2005-03-07 CA CA002558766A patent/CA2558766A1/en not_active Abandoned
- 2005-03-07 WO PCT/US2005/007435 patent/WO2005087234A1/en active Application Filing
- 2005-03-07 US US10/591,923 patent/US7932268B2/en active Active
- 2005-03-07 JP JP2007502093A patent/JP5697296B2/ja active Active
- 2005-03-07 AU AU2005221656A patent/AU2005221656B2/en active Active
- 2005-03-07 KR KR1020067020836A patent/KR20060129082A/ko not_active Application Discontinuation
- 2005-03-07 CA CA2910191A patent/CA2910191C/en active Active
- 2005-03-07 EP EP05724887.4A patent/EP1725234B2/en active Active
- 2005-03-07 SI SI200531669T patent/SI1725234T1/sl unknown
- 2005-03-07 NZ NZ549721A patent/NZ549721A/en unknown
- 2005-03-07 ME MEP-2013-155A patent/ME02070B/me unknown
- 2005-03-07 SI SI200531669A patent/SI1725234T2/sl unknown
- 2005-03-07 PT PT57248874T patent/PT1725234E/pt unknown
- 2005-03-07 PL PL05724887T patent/PL1725234T5/pl unknown
-
2011
- 2011-03-11 US US13/046,118 patent/US8618135B2/en active Active
-
2012
- 2012-07-19 JP JP2012160413A patent/JP2012232995A/ja not_active Withdrawn
-
2013
- 2013-02-08 HR HRP20130115TT patent/HRP20130115T4/hr unknown
- 2013-02-18 CY CY20131100149T patent/CY1114218T1/el unknown
- 2013-11-08 US US14/075,483 patent/US9265758B2/en active Active
- 2013-12-20 NL NL300634C patent/NL300634I2/nl unknown
-
2014
- 2014-01-02 LT LTPA2014001C patent/LTC1725234I2/lt unknown
- 2014-01-27 CY CY2014007C patent/CY2014007I1/el unknown
- 2014-06-30 JP JP2014134070A patent/JP5902760B2/ja active Active
-
2015
- 2015-12-04 US US14/959,756 patent/US9364470B2/en active Active
- 2015-12-17 JP JP2015245980A patent/JP6189918B2/ja active Active
-
2016
- 2016-05-16 US US15/155,647 patent/US9433617B1/en active Active
- 2016-07-25 US US15/218,670 patent/US9861622B2/en active Active
-
2017
- 2017-05-25 US US15/605,548 patent/US10016404B2/en active Active
-
2018
- 2018-07-09 US US16/030,703 patent/US10555938B2/en active Active
-
2020
- 2020-08-19 US US16/997,164 patent/US11554113B2/en active Active
-
2022
- 2022-12-09 US US18/063,803 patent/US20230109871A1/en not_active Abandoned
-
2023
- 2023-08-04 US US18/365,406 patent/US20230381166A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130115T4 (hr) | Postupci liječenja poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata | |
| JP2007527433A5 (hr) | ||
| HRP20200545T1 (hr) | Postupci liječenja ili sprječavanja poremećaja povezanih sa kolesterolom | |
| ES2274013T3 (es) | Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares. | |
| AU610178B2 (en) | Cough/cold mixtures comprising non-sedating antihistamine drugs | |
| US7390504B2 (en) | HDL-boosting combination therapy complexes | |
| US20030153541A1 (en) | Novel anticholesterol compositions and method for using same | |
| US11229634B2 (en) | Methods for treating gastrointestinal disorders using FXR agonists | |
| Mani et al. | Niacin therapy, HDL cholesterol, and cardiovascular disease: is the HDL hypothesis defunct? | |
| US20040092499A1 (en) | Methods and therapeutic combinations for the treatment of autoimmune disorders | |
| DE69534564D1 (de) | Verwendung von 2-hydroxy-5-phenylazobenzoesäure-derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs | |
| CA2626461A1 (en) | Compositions for lowering serum cholesterol and/or triglycerides | |
| WO2011019326A2 (en) | Solubility and stability enchancing pharmaceutical formulation | |
| Mahrooz | Pharmacological interactions of paraoxonase 1 (PON1): a HDL-bound antiatherogenic enzyme | |
| CA2502297A1 (en) | Compounds for the treatment of metabolic disorders | |
| EP2448564A2 (en) | Solubility enhancing pharmaceutical formulation | |
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| CA2853784A1 (en) | Treatment of blood lipid abnormalities and other conditions | |
| US20080125442A1 (en) | Cathepsin K Inhibitors and Atherosclerosis | |
| Yoshitomi et al. | Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study | |
| Brown | Therapies on the horizon for cholesterol reduction | |
| WO1998001100A2 (en) | Method for treating homozygous familial hypercholesterolemia | |
| Brousseau et al. | New targets for medical treatment of lipid disorders | |
| CA2657394A1 (en) | Preparation containing fibrate agent and process for producing the same | |
| ES2346969T3 (es) | Uso de inhibidores de trombina de bajo peso molecular en terapia de disminucion de colesterol. |